vs

Side-by-side financial comparison of COMPASS MINERALS INTERNATIONAL INC (CMP) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

COMPASS MINERALS INTERNATIONAL INC is the larger business by last-quarter revenue ($396.1M vs $207.3M, roughly 1.9× Ultragenyx Pharmaceutical Inc.). COMPASS MINERALS INTERNATIONAL INC runs the higher net margin — 4.7% vs -62.0%, a 66.7% gap on every dollar of revenue. On growth, COMPASS MINERALS INTERNATIONAL INC posted the faster year-over-year revenue change (28.9% vs 25.9%). COMPASS MINERALS INTERNATIONAL INC produced more free cash flow last quarter ($-59.8M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 4.3%).

Compass Minerals International, Inc is an American public company that, through its subsidiaries, is a leading producer of minerals, including salt, magnesium chloride and sulfate of potash. Based in Overland Park, Kansas; the company provides bulk treated and untreated highway deicing salt to customers in North America and the United Kingdom and plant nutrition products to growers worldwide. Compass Minerals also produces consumer deicing and water conditioning products, consumer and commerc...

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

CMP vs RARE — Head-to-Head

Bigger by revenue
CMP
CMP
1.9× larger
CMP
$396.1M
$207.3M
RARE
Growing faster (revenue YoY)
CMP
CMP
+3.0% gap
CMP
28.9%
25.9%
RARE
Higher net margin
CMP
CMP
66.7% more per $
CMP
4.7%
-62.0%
RARE
More free cash flow
CMP
CMP
$41.0M more FCF
CMP
$-59.8M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
4.3%
CMP

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CMP
CMP
RARE
RARE
Revenue
$396.1M
$207.3M
Net Profit
$18.6M
$-128.6M
Gross Margin
16.0%
Operating Margin
9.2%
-54.7%
Net Margin
4.7%
-62.0%
Revenue YoY
28.9%
25.9%
Net Profit YoY
178.8%
3.5%
EPS (diluted)
$0.43
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMP
CMP
RARE
RARE
Q4 25
$396.1M
$207.3M
Q3 25
$227.5M
$159.9M
Q2 25
$214.6M
$166.5M
Q1 25
$494.6M
$139.3M
Q4 24
$307.2M
$164.6M
Q3 24
$208.8M
$139.5M
Q2 24
$202.9M
$147.0M
Q1 24
$364.0M
$108.8M
Net Profit
CMP
CMP
RARE
RARE
Q4 25
$18.6M
$-128.6M
Q3 25
$-7.2M
$-180.4M
Q2 25
$-17.0M
$-115.0M
Q1 25
$-32.0M
$-151.1M
Q4 24
$-23.6M
$-133.2M
Q3 24
$-48.3M
$-133.5M
Q2 24
$-43.6M
$-131.6M
Q1 24
$-38.9M
$-170.7M
Gross Margin
CMP
CMP
RARE
RARE
Q4 25
16.0%
Q3 25
16.9%
Q2 25
19.2%
Q1 25
15.5%
Q4 24
11.2%
Q3 24
9.3%
Q2 24
16.1%
Q1 24
19.7%
Operating Margin
CMP
CMP
RARE
RARE
Q4 25
9.2%
-54.7%
Q3 25
5.3%
-106.9%
Q2 25
7.4%
-64.8%
Q1 25
-0.6%
-102.6%
Q4 24
0.2%
-74.3%
Q3 24
-14.3%
-94.6%
Q2 24
2.9%
-79.1%
Q1 24
-10.8%
-151.9%
Net Margin
CMP
CMP
RARE
RARE
Q4 25
4.7%
-62.0%
Q3 25
-3.2%
-112.8%
Q2 25
-7.9%
-69.0%
Q1 25
-6.5%
-108.5%
Q4 24
-7.7%
-80.9%
Q3 24
-23.1%
-95.7%
Q2 24
-21.5%
-89.5%
Q1 24
-10.7%
-156.8%
EPS (diluted)
CMP
CMP
RARE
RARE
Q4 25
$0.43
$-1.28
Q3 25
$-1.81
Q2 25
$-0.41
$-1.17
Q1 25
$-0.77
$-1.57
Q4 24
$-0.57
$-1.34
Q3 24
$-1.17
$-1.40
Q2 24
$-1.05
$-1.52
Q1 24
$-0.94
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMP
CMP
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$46.7M
$421.0M
Total DebtLower is stronger
$890.0M
Stockholders' EquityBook value
$260.5M
$-80.0M
Total Assets
$1.5B
$1.5B
Debt / EquityLower = less leverage
3.42×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMP
CMP
RARE
RARE
Q4 25
$46.7M
$421.0M
Q3 25
$59.7M
$202.5M
Q2 25
$79.4M
$176.3M
Q1 25
$49.5M
$127.1M
Q4 24
$45.8M
$174.0M
Q3 24
$20.2M
$150.6M
Q2 24
$12.8M
$480.7M
Q1 24
$38.3M
$112.3M
Total Debt
CMP
CMP
RARE
RARE
Q4 25
$890.0M
Q3 25
$839.8M
Q2 25
$833.4M
Q1 25
$807.6M
Q4 24
$974.4M
Q3 24
$921.2M
Q2 24
$875.1M
Q1 24
$877.2M
Stockholders' Equity
CMP
CMP
RARE
RARE
Q4 25
$260.5M
$-80.0M
Q3 25
$234.1M
$9.2M
Q2 25
$249.8M
$151.3M
Q1 25
$236.5M
$144.2M
Q4 24
$263.0M
$255.0M
Q3 24
$316.6M
$346.8M
Q2 24
$352.1M
$432.4M
Q1 24
$400.4M
$140.3M
Total Assets
CMP
CMP
RARE
RARE
Q4 25
$1.5B
$1.5B
Q3 25
$1.5B
$1.2B
Q2 25
$1.5B
$1.3B
Q1 25
$1.5B
$1.3B
Q4 24
$1.7B
$1.5B
Q3 24
$1.6B
$1.5B
Q2 24
$1.6B
$1.6B
Q1 24
$1.7B
$1.3B
Debt / Equity
CMP
CMP
RARE
RARE
Q4 25
3.42×
Q3 25
3.59×
Q2 25
3.34×
Q1 25
3.41×
Q4 24
3.70×
Q3 24
2.91×
Q2 24
2.49×
Q1 24
2.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMP
CMP
RARE
RARE
Operating Cash FlowLast quarter
$-37.0M
$-99.8M
Free Cash FlowOCF − Capex
$-59.8M
$-100.8M
FCF MarginFCF / Revenue
-15.1%
-48.6%
Capex IntensityCapex / Revenue
5.8%
0.5%
Cash ConversionOCF / Net Profit
-1.99×
TTM Free Cash FlowTrailing 4 quarters
$94.1M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMP
CMP
RARE
RARE
Q4 25
$-37.0M
$-99.8M
Q3 25
$-6.9M
$-91.4M
Q2 25
$21.8M
$-108.3M
Q1 25
$186.9M
$-166.5M
Q4 24
$-4.1M
$-79.3M
Q3 24
$-12.7M
$-67.0M
Q2 24
$-6.8M
$-77.0M
Q1 24
$86.2M
$-190.7M
Free Cash Flow
CMP
CMP
RARE
RARE
Q4 25
$-59.8M
$-100.8M
Q3 25
$-22.8M
$-92.7M
Q2 25
$3.8M
$-110.7M
Q1 25
$172.9M
$-167.8M
Q4 24
$-25.9M
$-79.5M
Q3 24
$-33.6M
$-68.6M
Q2 24
$-21.5M
$-79.0M
Q1 24
$56.2M
$-193.9M
FCF Margin
CMP
CMP
RARE
RARE
Q4 25
-15.1%
-48.6%
Q3 25
-10.0%
-58.0%
Q2 25
1.8%
-66.5%
Q1 25
35.0%
-120.5%
Q4 24
-8.4%
-48.3%
Q3 24
-16.1%
-49.2%
Q2 24
-10.6%
-53.7%
Q1 24
15.4%
-178.2%
Capex Intensity
CMP
CMP
RARE
RARE
Q4 25
5.8%
0.5%
Q3 25
7.0%
0.8%
Q2 25
8.4%
1.5%
Q1 25
2.8%
1.0%
Q4 24
7.1%
0.1%
Q3 24
10.0%
1.2%
Q2 24
7.2%
1.4%
Q1 24
8.2%
3.0%
Cash Conversion
CMP
CMP
RARE
RARE
Q4 25
-1.99×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CMP
CMP

Highway Deicing Salt$210.8M53%
Consumer Industrial Salt$120.7M30%
Plant Nutrition$60.8M15%
Transferred Over Time$2.8M1%
Other$1.0M0%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons